Comparative Pharmacology
Head-to-head clinical analysis: AKRINOL versus RENOVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKRINOL versus RENOVA.
AKRINOL vs RENOVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
Renova (tretinoin) is a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRα, RXRβ, RXRγ). It modulates gene expression, increasing collagen synthesis, reducing collagen breakdown via inhibition of matrix metalloproteinases, and promoting epidermal cell turnover and proliferation.
Adults: 100 mg orally twice daily.
Apply a thin layer to affected area once daily at bedtime. Use only fingertips to apply (0.1% cream).
None Documented
None Documented
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless CrCl <30 mL/min).
Terminal half-life is 2-4 hours in patients with normal renal function; prolonged to 18-24 hours in end-stage renal disease
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Renal (approximately 99% as unchanged drug), biliary/fecal (<1%)
Category C
Category C
Topical Retinoid
Topical Retinoid